RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Galapagos
G

Galapagos portfolio

Galapagos has 3 portfolio companies on record at Recent Funding, with 1 investment in the last 12 months.

Type: Investor.
Portfolio on Recent Funding: 3.
Deals, last 12 months: 1.
Capital in their rounds: $132M.
Latest deal: Third Arc Bio · Feb 4, 2026.
About this page

Its most recent investment on record is Third Arc Bio's $52M Series A round in February 2026, alongside Aberdeen, Marshall Wace, Goldman Sachs Alternatives and 6 others. By category, its portfolio leans toward Health and bio (2) and In-person and live experiences (1). It has co-invested with Andreessen Horowitz, T. Rowe Price and Biotechnology Value Fund.

What Galapagos invests in

How Galapagos invests

StageDealsCapital in rounds
Series B+ 1 50%$80M
Series A 1 50%$52M
YearDealsCapital in rounds
2024 1 50%$80M
2026 1 50%$52M

Galapagos portfolio companies

CompanyRound with GalapagosTotal raisedLatest raise
TThird Arc Bio
Health and bio
 Series A · $52M$217MFeb 4, 2026
Series A
FFrontier Medicines
Health and bio
 Series B+ · $80M$235.5MAug 28, 2025
Series B+
IIngresse
In-person and live experiences
 backerundisclosed—

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Share is of the 2 rounds on Recent Funding that name Galapagos. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists Galapagos, which is a subset of its real portfolio. API: /api/v1/investors/galapagos (get a free API key). More: the most active VC firms and new venture capital funds.